PortfoliosLab logoPortfoliosLab logo
AGIO vs. NVO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AGIO vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Agios Pharmaceuticals, Inc. (AGIO) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AGIO achieves a 10.29% return, which is significantly higher than NVO's -4.23% return. Over the past 10 years, AGIO has underperformed NVO with an annualized return of -3.95%, while NVO has yielded a comparatively higher 7.55% annualized return.


AGIO

1D
-8.34%
1M
-20.12%
6M
9.40%
YTD
10.29%
1Y
-14.23%
3Y*
3.87%
5Y*
-8.99%
10Y*
-3.95%
ALL TIME*
0.27%

NVO

1D
-8.78%
1M
-6.64%
6M
-18.01%
YTD
-4.23%
1Y
2.25%
3Y*
-14.32%
5Y*
2.48%
10Y*
7.55%
ALL TIME*
14.37%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$51.87M$46.01M$36.85M
$504.41M$480.49M$577.88M

AGIO vs. NVO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AGIO
Agios Pharmaceuticals, Inc.
10.29%-17.16%47.55%-20.69%-14.57%-24.14%-9.26%3.56%-19.35%37.00%
NVO
Novo Nordisk A/S
-4.23%-39.22%-15.93%54.84%22.66%63.52%23.33%28.70%-12.98%52.92%

Correlation

The correlation between AGIO and NVO is 0.23, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.23

Correlation (3Y)
Balances recent behavior with more history.

0.20

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.20

Correlation (10Y)
Provides a long-term view across more market conditions.

0.20

Correlation (All Time)
Calculated using the full available price history since Jul 24, 2013

0.22

Fundamentals

Market Cap

AGIO:

$1.79B

NVO:

$209.19B

EPS

AGIO:

-$7.01

NVO:

DKK 27.42

PS Ratio

AGIO:

17.92

NVO:

4.15

PB Ratio

AGIO:

1.74

NVO:

6.70

Total Revenue (TTM)

AGIO:

$98.34M

NVO:

DKK 327.80B

Gross Profit (TTM)

AGIO:

$86.46M

NVO:

DKK 268.30B

EBITDA (TTM)

AGIO:

-$418.15M

NVO:

DKK 181.54B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AGIO vs. NVO — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

AGIO
AGIO Risk / Return Rank: 3636
Overall Rank
AGIO Sharpe Ratio Rank: 3333
Sharpe Ratio Rank
AGIO Sortino Ratio Rank: 3939
Sortino Ratio Rank
AGIO Omega Ratio Rank: 4343
Omega Ratio Rank
AGIO Calmar Ratio Rank: 3131
Calmar Ratio Rank
AGIO Martin Ratio Rank: 3232
Martin Ratio Rank

NVO
NVO Risk / Return Rank: 4747
Overall Rank
NVO Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
NVO Sortino Ratio Rank: 4545
Sortino Ratio Rank
NVO Omega Ratio Rank: 4646
Omega Ratio Rank
NVO Calmar Ratio Rank: 4848
Calmar Ratio Rank
NVO Martin Ratio Rank: 4848
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

AGIO vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Agios Pharmaceuticals, Inc. (AGIO) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


AGIONVODifference
Sharpe ratioReturn per unit of total volatility

-0.35

Sortino ratioReturn per unit of downside risk

-0.22

Omega ratioGain probability vs. loss probability

1.05

1.06

-0.01

Calmar ratioReturn relative to maximum drawdown

-0.38

0.11

-0.49

Martin ratioReturn relative to average drawdown

-0.66

0.20

-0.85

AGIO vs. NVO - Sharpe Ratio Comparison

The current AGIO Sharpe Ratio is -0.25, which is lower than the NVO Sharpe Ratio of 0.10. The chart below compares the historical Sharpe Ratios of AGIO and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

AGIO vs. NVO - Drawdown Comparison

The maximum AGIO drawdown since its inception was -87.36%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for AGIO and NVO.


Loading charts...

Drawdown Indicators


AGIONVODifference

Max Drawdown

Largest peak-to-trough decline

-87.36%

-74.70%

-12.66%

Max Drawdown (1Y)

Largest decline over 1 year

-50.89%

-43.67%

-7.22%

Max Drawdown (3Y)

Largest decline over 3 years

-63.76%

-74.70%

+10.94%

Max Drawdown (5Y)

Largest decline over 5 years

-65.73%

-74.70%

+8.97%

Max Drawdown (10Y)

Largest decline over 10 years

-82.86%

-74.70%

-8.16%

Current Drawdown

Current decline from peak

-77.76%

-65.79%

-11.97%

Average Drawdown

Average peak-to-trough decline

-59.00%

-17.93%

-41.07%

Ulcer Index

Depth and duration of drawdowns from previous peaks

29.43%

23.97%

+5.46%

Volatility

AGIO vs. NVO - Volatility Comparison

Agios Pharmaceuticals, Inc. (AGIO) has a higher volatility of 22.65% compared to Novo Nordisk A/S (NVO) at 12.28%. This indicates that AGIO's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AGIONVODifference

Volatility (1M)

Calculated over the trailing 1-month period

22.65%

12.28%

+10.37%

Volatility (6M)

Calculated over the trailing 6-month period

45.99%

36.87%

+9.12%

Volatility (1Y)

Calculated over the trailing 1-year period

77.63%

46.77%

+30.86%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

59.62%

38.76%

+20.86%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

56.97%

32.76%

+24.21%

Dividends

AGIO vs. NVO - Dividend Comparison

AGIO has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.83%.


PositionTTM20252024202320222021202020192018201720162015
AGIO
Agios Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVO
Novo Nordisk A/S
3.83%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%

Financials

AGIO vs. NVO - Financials Comparison

This section allows you to compare key financial metrics between Agios Pharmaceuticals, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


AGIO and NVO have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AGIO has higher volatility (22.65%) compared to NVO (12.28%). In terms of maximum drawdown, AGIO dropped -87.36% vs NVO's -74.70%.

NVO currently has the higher Sharpe Ratio (0.10 vs -0.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AGIO and NVO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer